PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28938567-0 2017 Gemcitabine-induced heparanase promotes aggressiveness of pancreatic cancer cells via activating EGFR signaling. gemcitabine 0-11 epidermal growth factor receptor Homo sapiens 97-101 28938567-8 2017 Taken together, our results demonstrated that gemcitabine-induced HPA1 promotes proliferation and invasion of PC cells through activating EGFR, implying that HPA1 may serve as promising therapeutic target in the treatment of PC. gemcitabine 46-57 epidermal growth factor receptor Homo sapiens 138-142 27101576-1 2016 OBJECTIVES: The success of gemcitabine plus radiotherapy is dependent on the mutation status of pancreatic ductal adenocarcinoma (PDAC) tumors in the EGFR and KRAS genes; however, radiotherapy resistance may also be modulated epigenetically by microRNA (miRNA) regulation. gemcitabine 27-38 epidermal growth factor receptor Homo sapiens 150-154 32263194-13 2016 It"s significant to conjugate PHA-E for targeting cancer and inhibiting EGFR phosphorylation as it could decrease the dosage of gemcitabine, which reduces side effects on normal tissue. gemcitabine 128-139 epidermal growth factor receptor Homo sapiens 72-76 27556697-0 2016 Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling. gemcitabine 0-11 epidermal growth factor receptor Homo sapiens 63-67 27556697-8 2016 Mechanistically, HAb18G/CD147 promoted gemcitabine-enhanced invasion by activating the EGFR (epidermal growth factor receptor)-STAT3 (signal transducer and activator of transcription 3) signaling pathway. gemcitabine 39-50 epidermal growth factor receptor Homo sapiens 87-91 27556697-8 2016 Mechanistically, HAb18G/CD147 promoted gemcitabine-enhanced invasion by activating the EGFR (epidermal growth factor receptor)-STAT3 (signal transducer and activator of transcription 3) signaling pathway. gemcitabine 39-50 epidermal growth factor receptor Homo sapiens 93-125 27556697-9 2016 Inhibition of EGFR-STAT3 signaling counteracted gemcitabine-enhanced invasion, and which relied on HAb18G/CD147 levels. gemcitabine 48-59 epidermal growth factor receptor Homo sapiens 14-18 26650486-1 2016 PURPOSE: Chemotherapy with platinum compounds and gemcitabine is frequently used in first-line treatment of advanced non-small cell lung cancer (NSCLC) patients in which tyrosine kinase inhibitors (EGFR or ALK) cannot be administered. gemcitabine 50-61 epidermal growth factor receptor Homo sapiens 198-202 27070783-8 2016 In PB-type cases receiving adjuvant gemcitabine, but not in untreated cases, high EGFR expression was significantly associated with a shorter OS and RFS, with a significant treatment interaction in relation to OS (pinteraction = 0.042). gemcitabine 36-47 epidermal growth factor receptor Homo sapiens 82-86 26656632-0 2016 EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model. gemcitabine 67-78 epidermal growth factor receptor Homo sapiens 0-4 26656632-1 2016 UNLABELLED: In this study, we have formulated redox-responsive epidermal growth factor receptor (EGFR)-targeted type B gelatin nanoparticles as a targeted vector for systemic delivery of gemcitabine therapy in pancreatic cancer. gemcitabine 187-198 epidermal growth factor receptor Homo sapiens 63-95 26656632-1 2016 UNLABELLED: In this study, we have formulated redox-responsive epidermal growth factor receptor (EGFR)-targeted type B gelatin nanoparticles as a targeted vector for systemic delivery of gemcitabine therapy in pancreatic cancer. gemcitabine 187-198 epidermal growth factor receptor Homo sapiens 97-101 26656632-4 2016 Our in vitro studies in Panc-1 human pancreatic ductal adenocarcinoma cells confirm that gemcitabine encapsulated in EGFR-targeted gelatin nanoparticles, released through disulfide bond cleavage, had a significantly improved cytotoxic profile. gemcitabine 89-100 epidermal growth factor receptor Homo sapiens 117-121 26656632-8 2016 In this study, the authors presented their formulation of redox-responsive epidermal growth factor receptor (EGFR)-targeted type B gelatin nanoparticles as a carrier for gemcitabine. gemcitabine 170-181 epidermal growth factor receptor Homo sapiens 75-107 26656632-8 2016 In this study, the authors presented their formulation of redox-responsive epidermal growth factor receptor (EGFR)-targeted type B gelatin nanoparticles as a carrier for gemcitabine. gemcitabine 170-181 epidermal growth factor receptor Homo sapiens 109-113 26046796-9 2015 CONCLUSIONS: Gemcitabine plus erlotinib is more effective than gemcitabine alone for treating metastatic pancreatic cancer patients, especially those with EGFR mutations. gemcitabine 13-24 epidermal growth factor receptor Homo sapiens 155-159 26626700-0 2016 EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer. gemcitabine 48-59 epidermal growth factor receptor Homo sapiens 0-4 26056353-1 2015 PURPOSE: Epidermal growth factor receptor (EGFR) inhibitors may improve both the therapeutic efficacy of radiotherapy and the radiosensitizing activity of gemcitabine. gemcitabine 155-166 epidermal growth factor receptor Homo sapiens 9-41 26056353-1 2015 PURPOSE: Epidermal growth factor receptor (EGFR) inhibitors may improve both the therapeutic efficacy of radiotherapy and the radiosensitizing activity of gemcitabine. gemcitabine 155-166 epidermal growth factor receptor Homo sapiens 43-47 25550550-5 2015 RESULTS: Treatment with a combination of KML001 and gemcitabine resulted in significant inhibition of cell proliferation, migration, and invasion, and significantly reduced EGFR and MMP2 expression compared to gemcitabine treatment-alone. gemcitabine 52-63 epidermal growth factor receptor Homo sapiens 173-177 25776490-0 2015 Molecularly targeted gemcitabine-loaded nanoparticulate system towards the treatment of EGFR overexpressing lung cancer. gemcitabine 21-32 epidermal growth factor receptor Homo sapiens 88-92 25776490-2 2015 In the present study, we have developed gemcitabine (GEM)-loaded cetuximab (CET) surface modified poly(lactic) acid (PLA) nanoparticles (NP) (CET-GEM/PLA NP) to target to epidermal growth factor receptor (EGFR) overexpressing non-small cell lung cancer (A549) cells. gemcitabine 40-51 epidermal growth factor receptor Homo sapiens 171-203 25776490-2 2015 In the present study, we have developed gemcitabine (GEM)-loaded cetuximab (CET) surface modified poly(lactic) acid (PLA) nanoparticles (NP) (CET-GEM/PLA NP) to target to epidermal growth factor receptor (EGFR) overexpressing non-small cell lung cancer (A549) cells. gemcitabine 40-51 epidermal growth factor receptor Homo sapiens 205-209 24142531-3 2014 The objective of the current study was to evaluate the contribution of a monoclonal antibody against EGFR, nimotuzumab, to standard gemcitabine therapy. gemcitabine 132-143 epidermal growth factor receptor Homo sapiens 101-105 25821636-5 2015 MATERIALS AND METHODS: A light-reactive gemcitabine intermediate synthesized utilizing succinimidyl 4,4-azipentanoate was covalently bound to anti-EGFR or anti-HER2/neu IgG by exposure to UV light (354-nm) resulting in the synthesis of covalent immunochemotherapeutics, gemcitabine-(C4-amide)-[anti-EGFR] and gemcitabine-(C4-amide)-[anti-HER2/neu]. gemcitabine 40-51 epidermal growth factor receptor Homo sapiens 147-151 25821636-5 2015 MATERIALS AND METHODS: A light-reactive gemcitabine intermediate synthesized utilizing succinimidyl 4,4-azipentanoate was covalently bound to anti-EGFR or anti-HER2/neu IgG by exposure to UV light (354-nm) resulting in the synthesis of covalent immunochemotherapeutics, gemcitabine-(C4-amide)-[anti-EGFR] and gemcitabine-(C4-amide)-[anti-HER2/neu]. gemcitabine 40-51 epidermal growth factor receptor Homo sapiens 299-303 25821636-5 2015 MATERIALS AND METHODS: A light-reactive gemcitabine intermediate synthesized utilizing succinimidyl 4,4-azipentanoate was covalently bound to anti-EGFR or anti-HER2/neu IgG by exposure to UV light (354-nm) resulting in the synthesis of covalent immunochemotherapeutics, gemcitabine-(C4-amide)-[anti-EGFR] and gemcitabine-(C4-amide)-[anti-HER2/neu]. gemcitabine 270-281 epidermal growth factor receptor Homo sapiens 147-151 25821636-5 2015 MATERIALS AND METHODS: A light-reactive gemcitabine intermediate synthesized utilizing succinimidyl 4,4-azipentanoate was covalently bound to anti-EGFR or anti-HER2/neu IgG by exposure to UV light (354-nm) resulting in the synthesis of covalent immunochemotherapeutics, gemcitabine-(C4-amide)-[anti-EGFR] and gemcitabine-(C4-amide)-[anti-HER2/neu]. gemcitabine 270-281 epidermal growth factor receptor Homo sapiens 299-303 25821636-5 2015 MATERIALS AND METHODS: A light-reactive gemcitabine intermediate synthesized utilizing succinimidyl 4,4-azipentanoate was covalently bound to anti-EGFR or anti-HER2/neu IgG by exposure to UV light (354-nm) resulting in the synthesis of covalent immunochemotherapeutics, gemcitabine-(C4-amide)-[anti-EGFR] and gemcitabine-(C4-amide)-[anti-HER2/neu]. gemcitabine 270-281 epidermal growth factor receptor Homo sapiens 147-151 25821636-5 2015 MATERIALS AND METHODS: A light-reactive gemcitabine intermediate synthesized utilizing succinimidyl 4,4-azipentanoate was covalently bound to anti-EGFR or anti-HER2/neu IgG by exposure to UV light (354-nm) resulting in the synthesis of covalent immunochemotherapeutics, gemcitabine-(C4-amide)-[anti-EGFR] and gemcitabine-(C4-amide)-[anti-HER2/neu]. gemcitabine 270-281 epidermal growth factor receptor Homo sapiens 299-303 24838526-0 2014 Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. gemcitabine 0-11 epidermal growth factor receptor Homo sapiens 43-47 25844392-0 2014 Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole. gemcitabine 32-43 epidermal growth factor receptor Homo sapiens 61-65 25844392-2 2014 METHODOLOGY: Gemcitabine and epirubicin were covalently bond to anti-EGFR and anti-HER2/neu utilizing a rapid multi-phase synthetic organic chemistry reaction scheme. gemcitabine 13-24 epidermal growth factor receptor Homo sapiens 69-73 25844392-8 2014 Lastly, the tubulin/microtubule inhibitor mebendazole evaluated to determine if it"s potential to complemented the anti-neoplastic cytotoxic properties of gemcitabine-(C4-amide)-[anti-EGFR] in dual-combination with epirubicin-(C3-amide)-[anti-HER2/neu]. gemcitabine 155-166 epidermal growth factor receptor Homo sapiens 184-188 25844392-9 2014 RESULTS: Dual-combination of gemcitabine-(C4-amide)-[anti-EGFR] with epirubicin-(C3-amide)-[anti-HER2/neu] produced greater levels of anti-neoplastic cytotoxicity than either of the covalent immunochemotherapeutics alone. gemcitabine 29-40 epidermal growth factor receptor Homo sapiens 58-62 25041791-2 2014 We tested the hypothesis that simulataneous targeting of the epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) pathways would significantly improve progression-free survival (PFS) by abrogating reciprocal signaling that promote drug resistance METHODS: This was a phase Ib/II study testing cixutumumab, combined with erlotinib and gemcitabine (G) in patients with untreated metastatic PC. gemcitabine 372-383 epidermal growth factor receptor Homo sapiens 61-93 25041791-2 2014 We tested the hypothesis that simulataneous targeting of the epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) pathways would significantly improve progression-free survival (PFS) by abrogating reciprocal signaling that promote drug resistance METHODS: This was a phase Ib/II study testing cixutumumab, combined with erlotinib and gemcitabine (G) in patients with untreated metastatic PC. gemcitabine 372-383 epidermal growth factor receptor Homo sapiens 95-99 23910066-8 2013 Among the patients with EGFR mutations, the disease control rate for docetaxel was higher than for gemcitabine-based therapy (P = .031). gemcitabine 99-110 epidermal growth factor receptor Homo sapiens 24-28 23910066-9 2013 In addition, docetaxel or vinorelbine showed a longer PFS than gemcitabine-based chemotherapy in patients with EGFR mutations (P = .033 and P = .028). gemcitabine 63-74 epidermal growth factor receptor Homo sapiens 111-115 23910066-12 2013 In patients with EGFR mutations, PFS for docetaxel and gemcitabine was higher than for vinorelbine-based chemotherapies. gemcitabine 55-66 epidermal growth factor receptor Homo sapiens 17-21 23456778-3 2013 PATIENTS AND METHODS: Chinese patients >= 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). gemcitabine 245-256 epidermal growth factor receptor Homo sapiens 146-150 24025152-3 2013 The goal of this study was to identify molecular targets that are activated during gemcitabine therapy alone or in combination with an EGFR inhibitor. gemcitabine 83-94 epidermal growth factor receptor Homo sapiens 135-139 23890141-9 2013 Compared to gemcitabine-based chemotherapy alone, addition of an agent against EGFR resulted in significant longer OS [Hazard ratios (HR) 0.89 (0.79-0.99), p = 0.04] and longer PFS [HR 0.87 (0.79-0.97), p = 0.01], but no significant difference in ORR [RR 1.18 (0.82-1.70), p = 0.36]. gemcitabine 12-23 epidermal growth factor receptor Homo sapiens 79-83 23890141-11 2013 CONCLUSIONS: Addition of an agent against EGFR to gemcitabine-based chemotherapy improved OS compared to gemcitabine-based chemotherapy alone in patients with advanced pancreatic cancer, while addition of an agent against VEGFR showed a modest improvement in ORR but not PFS and OS. gemcitabine 50-61 epidermal growth factor receptor Homo sapiens 42-46 23890141-11 2013 CONCLUSIONS: Addition of an agent against EGFR to gemcitabine-based chemotherapy improved OS compared to gemcitabine-based chemotherapy alone in patients with advanced pancreatic cancer, while addition of an agent against VEGFR showed a modest improvement in ORR but not PFS and OS. gemcitabine 105-116 epidermal growth factor receptor Homo sapiens 42-46 23420122-0 2013 Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines. gemcitabine 46-57 epidermal growth factor receptor Homo sapiens 61-65 23420122-0 2013 Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines. gemcitabine 46-57 epidermal growth factor receptor Homo sapiens 84-88 23420122-3 2013 We also investigated the efficacy of concurrent and sequential administration of sorafenib and gemcitabine in epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-sensitive and EGFR-TKI-resistant NSCLC cell lines. gemcitabine 95-106 epidermal growth factor receptor Homo sapiens 110-142 23420122-3 2013 We also investigated the efficacy of concurrent and sequential administration of sorafenib and gemcitabine in epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-sensitive and EGFR-TKI-resistant NSCLC cell lines. gemcitabine 95-106 epidermal growth factor receptor Homo sapiens 144-148 22521649-10 2012 When we analyzed patients with an EGFR exon 19 deletion, the PFS of the taxane treated cases was better than that of the gemcitabine treated cases (5.3 months vs 3.7 months, P=0.012). gemcitabine 121-132 epidermal growth factor receptor Homo sapiens 34-38 23255896-0 2013 Sorafenib combined with gemcitabine in EGFR-TKI-resistant human lung cancer cells. gemcitabine 24-35 epidermal growth factor receptor Homo sapiens 39-43 23255896-2 2013 In this study, we explored in vitro the antitumor effects of sorafenib alone and in combination with gemcitabine in epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)-resistant human lung cancer cell lines and the related molecular mechanisms. gemcitabine 101-112 epidermal growth factor receptor Homo sapiens 176-180 23030589-5 2012 We utilized a nuclease resistant RNA aptamer that binds and is internalized by EGFR on pancreatic cancer cells to deliver gemcitabine-containing polymers into EGFR-expressing cells and inhibit cell proliferation in vitro. gemcitabine 122-133 epidermal growth factor receptor Homo sapiens 79-83 23030589-5 2012 We utilized a nuclease resistant RNA aptamer that binds and is internalized by EGFR on pancreatic cancer cells to deliver gemcitabine-containing polymers into EGFR-expressing cells and inhibit cell proliferation in vitro. gemcitabine 122-133 epidermal growth factor receptor Homo sapiens 159-163 22521649-11 2012 CONCLUSIONS: Our current data indicate that lung cancer patients with EGFR-mutations had longer PFS with taxane than gemcitabine when receiving a platinum-based doublet regimen. gemcitabine 117-128 epidermal growth factor receptor Homo sapiens 70-74 21970876-1 2011 BACKGROUND: The combination of the reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib with gemcitabine obtained FDA approval for treating patients with pancreatic cancer. gemcitabine 133-144 epidermal growth factor receptor Homo sapiens 46-78 22186617-5 2012 An exception to this is the anti-epidermal growth factor receptor therapy erlotinib, which yielded a survival benefit in patients with advanced disease in combination with gemcitabine compared with gemcitabine alone, although this was a marginal incremental improvement for which the clinical significant has been heavily debated. gemcitabine 172-183 epidermal growth factor receptor Homo sapiens 33-65 21970876-1 2011 BACKGROUND: The combination of the reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib with gemcitabine obtained FDA approval for treating patients with pancreatic cancer. gemcitabine 133-144 epidermal growth factor receptor Homo sapiens 80-84 21850211-0 2011 Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt. gemcitabine 0-11 epidermal growth factor receptor Homo sapiens 46-50 20705357-7 2011 However, for patients who had received first-line docetaxel/gemcitabine, overall survival was 14.8 months with EGFR TKIs and 10.8 months with chemotherapy (P = 0.29). gemcitabine 60-71 epidermal growth factor receptor Homo sapiens 111-115 21498735-3 2011 In preclinical models, exposure of pancreatic cancer cell lines to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor plus gemcitabine suggested enhanced cytotoxicity of gemcitabine and induced apoptosis in tumor cells. gemcitabine 188-199 epidermal growth factor receptor Homo sapiens 70-102 21498735-3 2011 In preclinical models, exposure of pancreatic cancer cell lines to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor plus gemcitabine suggested enhanced cytotoxicity of gemcitabine and induced apoptosis in tumor cells. gemcitabine 188-199 epidermal growth factor receptor Homo sapiens 104-108 21498735-4 2011 Erlotinib inhibited gemcitabine-induced phosphorylation of EGFR, which may promote cytotoxicity from gemcitabine. gemcitabine 20-31 epidermal growth factor receptor Homo sapiens 59-63 21498735-4 2011 Erlotinib inhibited gemcitabine-induced phosphorylation of EGFR, which may promote cytotoxicity from gemcitabine. gemcitabine 101-112 epidermal growth factor receptor Homo sapiens 59-63 21243324-0 2011 High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. gemcitabine 97-108 epidermal growth factor receptor Homo sapiens 5-9 21243324-1 2011 Pancreatic ductal adenocarcinoma (PDAC) still presents a major therapeutic challenge and a phase III clinical trial has revealed that the combination of gemcitabine and a human epidermal growth factor receptor type I (HER1/EGFR) targeting agent presented a significant benefit compared to treatment with gemcitabine alone. gemcitabine 304-315 epidermal growth factor receptor Homo sapiens 218-222 21243324-1 2011 Pancreatic ductal adenocarcinoma (PDAC) still presents a major therapeutic challenge and a phase III clinical trial has revealed that the combination of gemcitabine and a human epidermal growth factor receptor type I (HER1/EGFR) targeting agent presented a significant benefit compared to treatment with gemcitabine alone. gemcitabine 304-315 epidermal growth factor receptor Homo sapiens 223-227 21243324-5 2011 However, we found that high EGFR expression was an independent prognostic factor in patients receiving gemcitabine-based adjuvant chemotherapy (p=0.023). gemcitabine 103-114 epidermal growth factor receptor Homo sapiens 28-32 21243324-8 2011 In conclusion, quantitative analysis of EGFR mRNA expression using FFPE tissue samples and microdissected neoplastic cells from EUS-FNA cytological specimens could be useful in predicting prognosis and sensitivity to gemcitabine in PDAC patients. gemcitabine 217-228 epidermal growth factor receptor Homo sapiens 40-44 21485840-0 2011 EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer. gemcitabine 39-50 epidermal growth factor receptor Homo sapiens 0-4 21485840-1 2011 The present study aimed to prepare and characterize anti EGFR monoclonal antibody (mab) conjugated Gemcitabine loaded PLGA nanoparticles for their selective delivery to pancreatic cells and evaluation of the systems in vitro. gemcitabine 99-110 epidermal growth factor receptor Homo sapiens 57-61 21080748-1 2011 We report the case of a male Mongolian lifelong non-smoker with recurrent non-small-cell lung cancer (NSCLC) who developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib after initially responding to this agent but then subsequently had another response to a second course of erlotinib treatment after intervening gemcitabine chemotherapy. gemcitabine 361-372 epidermal growth factor receptor Homo sapiens 141-173 21080748-1 2011 We report the case of a male Mongolian lifelong non-smoker with recurrent non-small-cell lung cancer (NSCLC) who developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib after initially responding to this agent but then subsequently had another response to a second course of erlotinib treatment after intervening gemcitabine chemotherapy. gemcitabine 361-372 epidermal growth factor receptor Homo sapiens 175-179 21850211-9 2011 Our data show that gemcitabine increased the cytotoxic effect of erlotinib by downregulating p-Akt in EGFR-overexpressing cells with either intrinsic or acquired erlotinib resistance. gemcitabine 19-30 epidermal growth factor receptor Homo sapiens 102-106 21850211-3 2011 We studied the synergistic effect of erlotinib and gemcitabine in EGFR-overexpressing A-431 cells with acquired erlotinib resistance and in intrinsic erlotinib-resistant triple negative breast cancer (TNBC) BT-549, MDA-MB-231 and MDA-MB-468 cell lines. gemcitabine 51-62 epidermal growth factor receptor Homo sapiens 66-70 20213764-3 2010 We hypothesized that the inhibition of NF-kappaB and COX-2 by B-DIM concurrently with the inhibition of EGFR by erlotinib will potentiate the anti-tumor effects of cytotoxic drug gemcitabine, which has been tested both in vitro and in vivo. gemcitabine 179-190 epidermal growth factor receptor Homo sapiens 104-108 20824720-1 2010 BACKGROUND: National Cancer Institute of Canada Clinical Trials Group PA.3 (NCIC CTG PA.3) was a phase 3 study (n = 569) that demonstrated benefits for overall survival and progression-free survival with the addition of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib to gemcitabine in patients with advanced pancreatic carcinoma (APC). gemcitabine 309-320 epidermal growth factor receptor Homo sapiens 224-256 20961434-9 2010 Because of the remarkable response to erlotinib plus gemcitabine, we performed tumor genotyping of the EGFR gene for response predicting mutations in exons 18, 19 and 21. gemcitabine 53-64 epidermal growth factor receptor Homo sapiens 103-107 20606093-3 2010 This trial was conducted to evaluate the contribution of an EGFR-targeted agent to standard gemcitabine therapy. gemcitabine 92-103 epidermal growth factor receptor Homo sapiens 60-64 21087480-0 2010 Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. gemcitabine 70-81 epidermal growth factor receptor Homo sapiens 10-14 20726858-8 2010 Treatment with gemcitabine, which reduced the cell viability and augmented the cell apoptotic rate, activated and subsequently attenuated ERK and EGFR signals. gemcitabine 15-26 epidermal growth factor receptor Homo sapiens 146-150 20726858-9 2010 However, gemcitabine, paclitaxel, or cisplatin treatment enhanced the Akt activation, heterodimer formation of EGFR with HER3, and secretion of amphiregulin, indicating that the presence of gemcitabine promoted the activity of targeted molecules including amphiregulin, Akt, and HER3 for pancreatic cancer therapy. gemcitabine 9-20 epidermal growth factor receptor Homo sapiens 111-115 18698032-7 2008 RESULTS: We found in vitro that gemcitabine induced phosphorylation of EGFR at Y845 and Y1173 that was blocked by erlotinib. gemcitabine 32-43 epidermal growth factor receptor Homo sapiens 71-75 22966286-4 2010 We then examined the effect of erlotinib and gemcitabine on the phosphorylation of epidermal growth factor receptor (EGFR). gemcitabine 45-56 epidermal growth factor receptor Homo sapiens 83-115 22966286-4 2010 We then examined the effect of erlotinib and gemcitabine on the phosphorylation of epidermal growth factor receptor (EGFR). gemcitabine 45-56 epidermal growth factor receptor Homo sapiens 117-121 22966286-5 2010 Erlotinib strongly suppressed, while gemcitabine augmented the phosphorylation of EGFR, which was completely blocked by erlotinib in the two cell lines. gemcitabine 37-48 epidermal growth factor receptor Homo sapiens 82-86 19536777-8 2010 A second-line therapy with a gemcitabine/platinum combination regimen resulted in better overall survival than erlotinib in patients with EGFR mutations (p = 0.035) but not in patients with wild-type EGFR (p = 0.785). gemcitabine 29-40 epidermal growth factor receptor Homo sapiens 138-142 19536777-8 2010 A second-line therapy with a gemcitabine/platinum combination regimen resulted in better overall survival than erlotinib in patients with EGFR mutations (p = 0.035) but not in patients with wild-type EGFR (p = 0.785). gemcitabine 29-40 epidermal growth factor receptor Homo sapiens 200-204 19454812-2 2009 EGFR inhibitors have shown efficacy as radiosensitizers and activity against metastatic pancreatic cancer when combined with gemcitabine. gemcitabine 125-136 epidermal growth factor receptor Homo sapiens 0-4 18980967-4 2008 Two of the most promising targets, described in this review, for improving the efficacy of gemcitabine radiation are epidermal growth factor receptor and checkpoint kinase 1. gemcitabine 91-102 epidermal growth factor receptor Homo sapiens 117-149 18698032-12 2008 CONCLUSIONS: These results show that the EGFR inhibitors cetuximab and erlotinib increase the efficacy of gemcitabine-radiation. gemcitabine 106-117 epidermal growth factor receptor Homo sapiens 41-45 18505070-10 2008 The horizon has been broadened by a recent report on a tyrosine kinase inhibitor, erlotinib (EGFR inhibitor) which has shown significantly longer median survival, when combined with gemcitabine versus gemcitabine alone. gemcitabine 182-193 epidermal growth factor receptor Homo sapiens 93-97 18418211-6 2008 The combination of gemcitabine and erlotinib, a small-molecule tyrosine kinase inhibitor of the human epidermal growth factor receptor, was recently approved by the US/European authorities for use in advanced disease. gemcitabine 19-30 epidermal growth factor receptor Homo sapiens 102-134 18505070-10 2008 The horizon has been broadened by a recent report on a tyrosine kinase inhibitor, erlotinib (EGFR inhibitor) which has shown significantly longer median survival, when combined with gemcitabine versus gemcitabine alone. gemcitabine 201-212 epidermal growth factor receptor Homo sapiens 93-97 12429651-1 2002 We determined whether blockade of the epidermal growth factor-receptor (EGF-R) signaling pathway by oral administration of the EGF-R tyrosine kinase inhibitor PKI166 can inhibit angiogenesis and growth of SN12PM6 human renal cell carcinoma (HRCC) in the kidney of nude mice and whether gemcitabine can potentiate these effects. gemcitabine 286-297 epidermal growth factor receptor Homo sapiens 38-70 17827452-7 2007 Gemcitabine can also stimulate epidermal growth factor receptor (EGFR) phosphorylation; inhibiting this effect with EGFR inhibitors can potentiate cytotoxicity and radiosensitization. gemcitabine 0-11 epidermal growth factor receptor Homo sapiens 31-63 17827452-7 2007 Gemcitabine can also stimulate epidermal growth factor receptor (EGFR) phosphorylation; inhibiting this effect with EGFR inhibitors can potentiate cytotoxicity and radiosensitization. gemcitabine 0-11 epidermal growth factor receptor Homo sapiens 65-69 17827452-7 2007 Gemcitabine can also stimulate epidermal growth factor receptor (EGFR) phosphorylation; inhibiting this effect with EGFR inhibitors can potentiate cytotoxicity and radiosensitization. gemcitabine 0-11 epidermal growth factor receptor Homo sapiens 116-120 17555368-5 2007 A Phase II trial of gemcitabine with the anti-EGFR antibody cetuximab resulted in a 1-year survival of 32%. gemcitabine 20-31 epidermal growth factor receptor Homo sapiens 46-50 17555368-7 2007 A Phase I trial of gemcitabine with the EGFR/Her-2 inhibitor, lapatinib, is completed. gemcitabine 19-30 epidermal growth factor receptor Homo sapiens 40-44 17146438-0 2007 Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. gemcitabine 56-67 epidermal growth factor receptor Homo sapiens 8-40 17146438-1 2007 We have recently reported that treatment with gemcitabine, a potent chemotherapeutic agent and radiation sensitizer, stimulates phosphorylation of the epidermal growth factor receptor (EGFR). gemcitabine 46-57 epidermal growth factor receptor Homo sapiens 151-183 17146438-1 2007 We have recently reported that treatment with gemcitabine, a potent chemotherapeutic agent and radiation sensitizer, stimulates phosphorylation of the epidermal growth factor receptor (EGFR). gemcitabine 46-57 epidermal growth factor receptor Homo sapiens 185-189 17146438-2 2007 Because phosphorylation of EGFR is known to precede receptor degradation, we hypothesized that gemcitabine treatment may also result in EGFR degradation. gemcitabine 95-106 epidermal growth factor receptor Homo sapiens 27-31 17146438-2 2007 Because phosphorylation of EGFR is known to precede receptor degradation, we hypothesized that gemcitabine treatment may also result in EGFR degradation. gemcitabine 95-106 epidermal growth factor receptor Homo sapiens 136-140 17146438-3 2007 In two human head and neck cancer cell lines, UMSCC-1 and UMSCC-6, we demonstrated an approximately 80% decrease in total EGFR levels at 72 h after a 2-h treatment with 1 muM gemcitabine. gemcitabine 175-186 epidermal growth factor receptor Homo sapiens 122-126 17146438-6 2007 Inhibition of EGFR degradation, by either pretreatment with the EGFR tyrosine kinase inhibitor gefitinib or by exposure to the proteosome/lysosome inhibitor MG132, significantly reduced gemcitabine-induced cell death. gemcitabine 186-197 epidermal growth factor receptor Homo sapiens 14-18 17146438-6 2007 Inhibition of EGFR degradation, by either pretreatment with the EGFR tyrosine kinase inhibitor gefitinib or by exposure to the proteosome/lysosome inhibitor MG132, significantly reduced gemcitabine-induced cell death. gemcitabine 186-197 epidermal growth factor receptor Homo sapiens 64-68 17146438-7 2007 These results suggest that EGFR degradation may be a novel mechanism for gemcitabine-mediated cell death. gemcitabine 73-84 epidermal growth factor receptor Homo sapiens 27-31 17845978-4 2007 This review sum-up the clinical situations in which gemcitabine can be prescribed (advanced disease), or shall be prescribed (adjuvant setting, combination with anti-angiogenic agent or EGFR inhibitors), and highlight opening questions. gemcitabine 52-63 epidermal growth factor receptor Homo sapiens 186-190 16621676-7 2006 In particular, cetuximab and erlotinib, the monoclonal antibodies against EGFR-1 (ErbB-1) showed promising activity in Phase II and Phase III trials and their combination with gemcitabine resulted in synergistic antitumor activity. gemcitabine 176-187 epidermal growth factor receptor Homo sapiens 74-78 16621676-7 2006 In particular, cetuximab and erlotinib, the monoclonal antibodies against EGFR-1 (ErbB-1) showed promising activity in Phase II and Phase III trials and their combination with gemcitabine resulted in synergistic antitumor activity. gemcitabine 176-187 epidermal growth factor receptor Homo sapiens 82-88 16621676-9 2006 Association of chemoresistance with the activity of certain tyrosine kinases (e.g. ErbB-1 and Src) has been described for pancreatic cancer and makes a strong case for combining gemcitabine with TKIs. gemcitabine 178-189 epidermal growth factor receptor Homo sapiens 83-97 16424033-6 2006 Gefitinib suppressed gemcitabine-mediated p(Y845)EGFR stimulation. gemcitabine 21-32 epidermal growth factor receptor Homo sapiens 49-53 16424033-8 2006 The schedule of gefitinib followed by gemcitabine also caused suppression of p(Y845)EGFR but arrested cells in G(1). gemcitabine 38-49 epidermal growth factor receptor Homo sapiens 84-88 16424033-11 2006 These findings suggest that the schedule of gemcitabine followed by gefitinib may increase the therapeutic index over gemcitabine alone and, combined with clinical data, encourage exploration of combination of gemcitabine, EGFR inhibitors, and radiation. gemcitabine 44-55 epidermal growth factor receptor Homo sapiens 223-227 17686445-2 2007 Impressive responses are observed in patients with epidermal growth factor receptor (EGFR) tyrosine kinase mutations following treatment with gefitinib and erlotinib; and methylation of the mitotic checkpoint gene 14-3-3sigma in circulating tumour serum DNA predicts response to cisplatin/gemcitabine therapy. gemcitabine 289-300 epidermal growth factor receptor Homo sapiens 85-89 16288027-10 2005 Thus, inhibiting phosphorylation of EGFR, VEGFR, and PDGFR in combination with gemcitabine enhanced the efficacy of gemcitabine, resulting in inhibition of experimental human pancreatic cancer growth and significant prolongation of survival. gemcitabine 116-127 epidermal growth factor receptor Homo sapiens 36-40 16026649-2 2005 We hypothesized that the inhibition of phosphorylation of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) on tumor cells and tumor-associated endothelial cells, combined with gemcitabine, would overcome the resistance to gemcitabine in orthotopic pancreatic tumor animal model. gemcitabine 223-234 epidermal growth factor receptor Homo sapiens 58-90 16026649-2 2005 We hypothesized that the inhibition of phosphorylation of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) on tumor cells and tumor-associated endothelial cells, combined with gemcitabine, would overcome the resistance to gemcitabine in orthotopic pancreatic tumor animal model. gemcitabine 223-234 epidermal growth factor receptor Homo sapiens 92-96 16026649-2 2005 We hypothesized that the inhibition of phosphorylation of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) on tumor cells and tumor-associated endothelial cells, combined with gemcitabine, would overcome the resistance to gemcitabine in orthotopic pancreatic tumor animal model. gemcitabine 269-280 epidermal growth factor receptor Homo sapiens 58-90 16026649-2 2005 We hypothesized that the inhibition of phosphorylation of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) on tumor cells and tumor-associated endothelial cells, combined with gemcitabine, would overcome the resistance to gemcitabine in orthotopic pancreatic tumor animal model. gemcitabine 269-280 epidermal growth factor receptor Homo sapiens 92-96 15226328-1 2004 PURPOSE: To determine the response rate, time to disease progression, survival duration and rate, and toxicity with the combination of cetuximab and gemcitabine in patients with epidermal growth factor receptor (EGFR)-expressing advanced pancreatic cancer. gemcitabine 149-160 epidermal growth factor receptor Homo sapiens 178-210 15226328-1 2004 PURPOSE: To determine the response rate, time to disease progression, survival duration and rate, and toxicity with the combination of cetuximab and gemcitabine in patients with epidermal growth factor receptor (EGFR)-expressing advanced pancreatic cancer. gemcitabine 149-160 epidermal growth factor receptor Homo sapiens 212-216 12429651-1 2002 We determined whether blockade of the epidermal growth factor-receptor (EGF-R) signaling pathway by oral administration of the EGF-R tyrosine kinase inhibitor PKI166 can inhibit angiogenesis and growth of SN12PM6 human renal cell carcinoma (HRCC) in the kidney of nude mice and whether gemcitabine can potentiate these effects. gemcitabine 286-297 epidermal growth factor receptor Homo sapiens 72-77 10850439-1 2000 We determined whether down-regulation of the epidermal growth factor-receptor (EGF-R) signaling pathway by oral administration of a novel EGF-R tyrosine kinase inhibitor (PKI166) alone or in combination with gemcitabine (administered i.p.) gemcitabine 208-219 epidermal growth factor receptor Homo sapiens 79-84 34238922-0 2021 Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer. gemcitabine 28-39 epidermal growth factor receptor Homo sapiens 99-103 10815919-0 2000 Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. gemcitabine 57-68 epidermal growth factor receptor Homo sapiens 0-32 34805140-0 2021 Effect of Photodynamic Therapy on Gemcitabine-Resistant Cholangiocarcinoma in vitro and in vivo Through KLF10 and EGFR. gemcitabine 34-45 epidermal growth factor receptor Homo sapiens 114-118 34805140-6 2021 Under PDT treatment, EGFR overexpression and KLF10 silencing attenuated the anti-cancer effects of PDT on gemcitabine-resistant cholangiocarcinoma cells by promoting cell viability, inhibiting apoptosis, and increasing S phase cell proportion. gemcitabine 106-117 epidermal growth factor receptor Homo sapiens 21-25 34805140-10 2021 The KLF10/EGFR axis participates in the process of the inhibition of PDT on gemcitabine-resistant cholangiocarcinoma cells. gemcitabine 76-87 epidermal growth factor receptor Homo sapiens 10-14 34061460-1 2021 A 72-year-old man, diagnosed with advanced lung squamous cell carcinoma, was administered of cisplatin plus gemcitabine with necitumumab, a human monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), as a sixth-line treatment. gemcitabine 108-119 epidermal growth factor receptor Homo sapiens 184-216 34061460-1 2021 A 72-year-old man, diagnosed with advanced lung squamous cell carcinoma, was administered of cisplatin plus gemcitabine with necitumumab, a human monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), as a sixth-line treatment. gemcitabine 108-119 epidermal growth factor receptor Homo sapiens 218-222 32924987-8 2021 Gene set variation analysis (GSVA) showed that activity in the cell cycle/mitotic, ERBB, and ERK/MAPK pathways was higher in the high-risk compared with the low-risk group, which may lead to differences in OS.Interestingly, we observed that patients in the high-risk group were more sensitive to gemcitabine and docetaxel than the low-risk group, which is consistent with results of the GSVA. gemcitabine 296-307 epidermal growth factor receptor Homo sapiens 83-87 34238922-12 2021 Moreover, ANXA6 and EGFR protein expression was correlated in TNBC tissues, and exosomal ANXA6 levels at baseline were lower in patients with highly sensitive TNBC than those with resistant TNBC when treated with first-line gemcitabine-based chemotherapy. gemcitabine 224-235 epidermal growth factor receptor Homo sapiens 20-24 34238922-13 2021 In conclusion, resistant cancer cell-derived exosomes induced gemcitabine resistance via exosomal ANXA6, which was associated with the inhibition of EGFR ubiquitination and degradation. gemcitabine 62-73 epidermal growth factor receptor Homo sapiens 149-153 34123574-6 2021 Priming of drug sensitive or resistant cells with EGFR BATs followed by retargeting with lower concentrations of 50% inhibitory concentration of gemcitabine or cisplatin showed enhanced cytotoxicity. gemcitabine 145-156 epidermal growth factor receptor Homo sapiens 50-54 33878513-5 2021 RESULTS: We found that CUDC-101 and gemcitabine interacted synergistically to reduce NHL cell viability and to induce the apoptotic death of these cells via the EGFR/ PI3K/Akt and Erk pathways, which were regulated by HDAC signaling pathways. gemcitabine 36-47 epidermal growth factor receptor Homo sapiens 161-165 33432347-0 2021 Epidermal growth factor receptor promotes tumor progression and contributes to gemcitabine resistance in osteosarcoma. gemcitabine 79-90 epidermal growth factor receptor Homo sapiens 0-32 33432347-5 2021 In this study, we aimed to investigate the role of EGFR in OS progression and in the response of OS to gemcitabine treatment. gemcitabine 103-114 epidermal growth factor receptor Homo sapiens 51-55 33432347-10 2021 Moreover, the level of phospho-EGFR was increased in OS cells when exposed to gemcitabine treatment. gemcitabine 78-89 epidermal growth factor receptor Homo sapiens 31-35 33432347-12 2021 On the contrary, EGFR overexpression counteracted the growth-inhibiting and pro-apoptotic effects of gemcitabine in OS cells. gemcitabine 101-112 epidermal growth factor receptor Homo sapiens 17-21 33432347-13 2021 The present study suggests that EGFR promotes tumor progression and contributes to gemcitabine resistance in OS. gemcitabine 83-94 epidermal growth factor receptor Homo sapiens 32-36 33288882-9 2021 Moreover, afatinib alone or in combination with gemcitabine decreased stemness and tumorspheres by reducing phosphorylation of EGFR family proteins, ERK, FAK, and CSC markers. gemcitabine 48-59 epidermal growth factor receptor Homo sapiens 127-131 32111744-5 2020 Patients treated with gemcitabine-based CHT plus EGFR-mAbs showed a statistically significant increased risk of grade 3-4 neutropenia, grade 3-4 thrombocytopenia and especially grade 3-4 skin rash. gemcitabine 22-33 epidermal growth factor receptor Homo sapiens 49-53 32622356-7 2020 CONCLUSION: This case reports the possible efficacy of erlotinib in combination with gemcitabine and oxaliplatin in treating an EGFR-mutated GBC with liver metastasis. gemcitabine 85-96 epidermal growth factor receptor Homo sapiens 128-132 32235891-0 2020 Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation. gemcitabine 72-83 epidermal growth factor receptor Homo sapiens 122-126 32111094-0 2020 Local Delivery of Gemcitabine Inhibits Pancreatic and Cholangiocarcinoma Tumor Growth by Promoting Epidermal Growth Factor Receptor Degradation. gemcitabine 18-29 epidermal growth factor receptor Homo sapiens 99-131 32111094-7 2020 We demonstrated that local delivery of gemcitabine using GEM implants inhibited tumor cell growth by promoting c-CBL-mediated degradation of EGFR and inhibiting the proliferation, angiogenesis, and epithelial-mesenchymal transition of pancreatic/biliary tumors. gemcitabine 39-50 epidermal growth factor receptor Homo sapiens 141-145 31387179-7 2019 In in vitro experiment, WEE1 expression was higher in EGFR-TKIs resistant than EGFR-TKIs sensitive cell lines and was gradually increased following cisplatin or gemcitabine treatment with the enrichment of G2/M cell cycle phase. gemcitabine 161-172 epidermal growth factor receptor Homo sapiens 54-58 31550632-0 2019 Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication. gemcitabine 180-191 epidermal growth factor receptor Homo sapiens 108-112 31550632-2 2019 In this work, a novel approach was adopted for detection and assessment of Gemcitabine (GEM) as an anti-cancer drug based on evaluating its interaction with EGFR exon 21-point mutant gene. gemcitabine 75-86 epidermal growth factor receptor Homo sapiens 157-161 31550632-2 2019 In this work, a novel approach was adopted for detection and assessment of Gemcitabine (GEM) as an anti-cancer drug based on evaluating its interaction with EGFR exon 21-point mutant gene. gemcitabine 88-91 epidermal growth factor receptor Homo sapiens 157-161 31387179-7 2019 In in vitro experiment, WEE1 expression was higher in EGFR-TKIs resistant than EGFR-TKIs sensitive cell lines and was gradually increased following cisplatin or gemcitabine treatment with the enrichment of G2/M cell cycle phase. gemcitabine 161-172 epidermal growth factor receptor Homo sapiens 79-83 29851753-2 2018 Epidermal growth factor receptor tyrosine kinase inhibitor erlotinib was approved to treat patients combining with gemcitabine. gemcitabine 115-126 epidermal growth factor receptor Homo sapiens 0-32 31289485-0 2019 Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin. gemcitabine 122-133 epidermal growth factor receptor Homo sapiens 67-71 30679315-1 2019 LESSONS LEARNED: Dual epidermal growth factor receptor (EGFR)-directed therapy with erlotinib and panitumumab in combination with gemcitabine was superior to gemcitabine and erlotinib, but the clinical relevance is uncertain given the limited role of gemcitabine monotherapy.A significantly longer overall survival was observed in patients receiving the dual EGFR-directed therapy.The dual EGFR-directed therapy resulted in increased toxicity. gemcitabine 130-141 epidermal growth factor receptor Homo sapiens 22-54 30679315-1 2019 LESSONS LEARNED: Dual epidermal growth factor receptor (EGFR)-directed therapy with erlotinib and panitumumab in combination with gemcitabine was superior to gemcitabine and erlotinib, but the clinical relevance is uncertain given the limited role of gemcitabine monotherapy.A significantly longer overall survival was observed in patients receiving the dual EGFR-directed therapy.The dual EGFR-directed therapy resulted in increased toxicity. gemcitabine 130-141 epidermal growth factor receptor Homo sapiens 56-60 30679315-3 2019 The combination of erlotinib, an oral epidermal growth factor receptor (EGFR) inhibitor, and gemcitabine was shown to modestly prolong overall survival when compared with gemcitabine alone. gemcitabine 171-182 epidermal growth factor receptor Homo sapiens 72-76 30407790-0 2018 Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation. gemcitabine 88-99 epidermal growth factor receptor Homo sapiens 0-32 30407790-5 2018 To address this issue, we have engineered an epidermal growth factor receptor (EGFR) targeting (with GE11 peptide) self-assembly amphiphilic peptide nanoparticle (GENP) to co-deliver gemcitabine and the PARPi olaparib to treat BRCA mutant PCa. gemcitabine 183-194 epidermal growth factor receptor Homo sapiens 45-77 30407790-5 2018 To address this issue, we have engineered an epidermal growth factor receptor (EGFR) targeting (with GE11 peptide) self-assembly amphiphilic peptide nanoparticle (GENP) to co-deliver gemcitabine and the PARPi olaparib to treat BRCA mutant PCa. gemcitabine 183-194 epidermal growth factor receptor Homo sapiens 79-83 29352306-1 2018 The association of anti-EGFR to gemcitabine and oxaliplatin (GEMOX) chemotherapy did not improve survival in biliary tract carcinoma (BTC) patients. gemcitabine 32-43 epidermal growth factor receptor Homo sapiens 24-28 29141539-3 2018 MATERIALS AND METHODS: Monophosphate analogs of fludarabine, gemcitabine, and dexamethasone were combined with a carbodiimide reagent in the presence of imidazole to produce reactive intermediates that were subsequently covalently bound to monoclonal anti-IGF-1R or anti-EGFR IgG-immunoglobulin. gemcitabine 61-72 epidermal growth factor receptor Homo sapiens 271-275 28719220-0 2017 EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer. gemcitabine 66-77 epidermal growth factor receptor Homo sapiens 0-4 28927112-0 2017 Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors. gemcitabine 71-82 epidermal growth factor receptor Homo sapiens 128-132 28927112-5 2017 It was revealed that lung cancer cells that had developed resistance to EGFR-TKIs had increased sensitivity to gemcitabine and vinorelbine compared with EGFR-TKI naive cells. gemcitabine 111-122 epidermal growth factor receptor Homo sapiens 72-76 28927112-7 2017 In addition, two cases were identified in which gemcitabine and vinorelbine exerted marked responses to lung cancers that had acquired resistance to EGFR-TKIs, even with late-line treatment. gemcitabine 48-59 epidermal growth factor receptor Homo sapiens 149-153 28927112-8 2017 Therefore, it was proposed that gemcitabine and vinorelbine may be effective agents for patients with lung cancer previously treated with EGFR-TKIs. gemcitabine 32-43 epidermal growth factor receptor Homo sapiens 138-142